Compare Incyte Corporation (INCY) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs KeyCorp — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while KeyCorp trades at $20.1 (market cap $21.16B). The key difference: Incyte Corporation and KeyCorp are close in size by market cap, and KeyCorp pays a 4.14% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and KeyCorp for 66 Days on average.
| INCY | KEY | |
|---|---|---|
Market Cap | $22.99B | $21.16B |
Volume | 1,274,487 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $129.93 | $23.99 |
52-Week Low | $83.80 | $16.78 |
Typical Hold Time | 33 Days | 66 Days |
Enterprise Value | $18.50B | $34.34B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
KeyCorp (KEY) trades at $20.1, down 0.2% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The stock shows attractive valuation with a P/E of 11.6 and a P/B of 1.22, supported by a strong net income margin of 26.72%. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments aimed at strengthening operations.
The outlook is positive with a consensus price target of $25.00, implying significant upside, driven by loan growth and net interest margin expansion. Risks include competitive pressure from peers raising dividends and macroeconomic sensitivity to interest rate changes. Earnings momentum and institutional buying provide a solid foundation for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
